MYELODYSPLASTIC
SYNDROMES
Exploring dysfunctional pathways, mechanisms, and biomarkers in MDS to
discover new insights into the progression of the disease.
Relevant Cancer Targets
BCL-2
Learn why the role BCL-2 plays in tumor survival makes it a rational target for therapeutic intervention.MORE>
- NCCN Guidelines®. Myelodysplastic Syndromes. V3.2021.
- National Cancer Institute. Myelodysplastic Syndromes Treatment (PDQ®)–Patient Version. https://www.cancer.gov/types/myeloproliferative/patient/myelodysplastic-treatment-pdq. Accessed April 2021.
- Pfeilstocker M, et al. Time-dependent changes in mortality and transformation risk in MDS. Blood. 2016;128(7):902-910.
- NCI. Cancer Stat Facts: Acute Myeloid Leukemia (AML). https://seer.cancer.gov/statfacts/html/amyl.html. Accessed November 2020.
- NCI. SEER*Explorer, Myelodysplastic Syndrome (MDS): https://seer.cancer.gov/explorer/. Accessed September 2021.
- Ye X, et al. The incidence, risk factors, and survival of acute myeloid leukemia secondary to myelodysplastic syndrome: A population-based study. Hematological Oncology. 2019;37:438–446.
- Ma, X. Epidemiology of Myelodysplastic Syndromes. Am J Med. 2012;125(7):S2–S5.
- Jilg S, et al. Blockade of BCL-2 proteins efficiently induces apoptosis in progenitor cells of high-risk myelodysplastic syndromes patients. Leukemia. 2016;30:112-123.
- Zhou T, et al. Potential Relationship between Inadequate Response to DNA Damage and Development of Myelodysplastic Syndrome. Int J Mol Sci. 2015;16:966-989.
- Ades L. Myelodysplastic syndromes. Lancet. 2014;383(9936):2239-52.
- Bejar, R. What biologic factors predict for transformation to AML? Best Practice & Research Clinical Haematology. 2018;31(4):341-345.
- Papaemmanuil E, et al. Clinical and biological implications of driver mutations in myelodysplastic syndromes. Blood. 2013;122(22):3616-3627.
- Bejar R, et al. Clinical effect of point mutations in myelodysplastic syndromes. N Engl J Med. 2011;364(26):2496-2506.
- Bejar R, et al. Recent developments in myelodysplastic syndromes. Blood. 2014;124(18):2793-803.
- Malcovati L, et al. Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European LeukemiaNet. Blood. 2013;122(17):2943-2964.
- Zeidan AM, et al. Epidemiology of myelodysplastic syndromes: Why characterizing the beast is a prerequisite to taming it. Blood Rev. 2019;34:1-15.
- CancerMPact® Treatment Architecture. MDS, EU5. Published August 2022. Cerner Enviza.
- Bernard E, et al. Molecular international prognostic scoring system for myelodysplastic syndromes. NEJM Evidence. 2022;1(7):EVIDoa2200008